Payment overview · 2025
General Payments
$683.40
28 reported records · 10 companies
Healthcare provider profile · identity verified
Mark Anthony Portacci, MD
Allopathic & Osteopathic Physicians|Family Medicine · OAK GROVE, LA · NPI 1265500490
Verified facts
What the public records show
CMS Open Payments records show Mark Anthony Portacci, MD received $683.40 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Nurtec Odt, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $243.35 | 35.6% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $97.83 | 14.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.04 | 11.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.53 | 8.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.52 | 6.4% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $42.61 | 6.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.11 | 5.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.51 | 4.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.69 | 4.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.21 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $683.40 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $243.35 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $81.24 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $76.04 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.43 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $42.61 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.51 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 196 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 106 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 270 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
111 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
196 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | 18 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
270 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
176 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 356 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 307 | 53 |
| Tramadol Hcl | Tramadol Hcl | 289 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 281 | 88 |
| Mounjaro | Tirzepatide | 270 | 52 |
| Losartan Potassium | Losartan Potassium | 246 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 81 |
| Montelukast Sodium | Montelukast Sodium | 222 | 65 |
| Potassium Chloride | Potassium Chloride | 214 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 60 |
| Farxiga | Dapagliflozin Propanediol | 196 | 39 |
| Clonazepam | Clonazepam | 192 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 182 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 40 |
| Eliquis | Apixaban | 176 | 31 |
| Lisinopril | Lisinopril | 172 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 170 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 48 |
| Nifedipine Er | Nifedipine | 147 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 41 |
| Ozempic | Semaglutide | 130 | 34 |
| Tramadol Hcl Er | Tramadol Hcl | 124 | 18 |
| Famotidine | Famotidine | 118 | 31 |
| Omeprazole | Omeprazole | 117 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 111 | 26 |
| Furosemide | Furosemide | 111 | 31 |
| Linzess | Linaclotide | 111 | 31 |
| Azithromycin | Azithromycin | 109 | 79 |
| Pregabalin | Pregabalin | 109 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 29 |
| Gemtesa | Vibegron | 106 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 21 |
| Alendronate Sodium | Alendronate Sodium | 103 | 24 |
| Donepezil Hcl | Donepezil Hcl | 103 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 26 |
| Jardiance | Empagliflozin | 98 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 29 |
| Levetiracetam | Levetiracetam | 90 | 11 |
| Naproxen | Naproxen | 86 | 29 |
| Trazodone Hcl | Trazodone Hcl | 84 | 18 |
| Meloxicam | Meloxicam | 83 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 14 |
| Entresto | Sacubitril/Valsartan | 71 | suppressed |
| Ibuprofen | Ibuprofen | 70 | 28 |
| Ondansetron Odt | Ondansetron | 70 | 22 |
| Alprazolam | Alprazolam | 69 | 11 |
| Allopurinol | Allopurinol | 68 | 16 |
| Mirtazapine | Mirtazapine | 66 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 15 |
| Kerendia | Finerenone | 57 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 17 |
| Belbuca | Buprenorphine Hcl | 52 | suppressed |
| Prednisone | Prednisone | 52 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 33 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 51 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 17 |
| Fluconazole | Fluconazole | 47 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Sertraline Hcl | Sertraline Hcl | 47 | 15 |
| Vraylar | Cariprazine Hcl | 47 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | 11 |
| Valsartan | Valsartan | 42 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 17 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 16 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 13 |
| Metformin Hcl | Metformin Hcl | 37 | 21 |
| Baclofen | Baclofen | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 32 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Latanoprost | Latanoprost | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 12 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Movantik | Naloxegol Oxalate | 28 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 25 |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Mupirocin | Mupirocin | 24 | 16 |
| Carvedilol | Carvedilol | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 22 |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 22 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $683.40 · 28 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, MYFEMBREE, NURTEC ODT, Ohtuvayre, VRAYLAR, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error